Literature DB >> 19022802

A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells.

Kathrin Zuberbühler1, Alessandro Palumbo, Camilla Bacci, Leonardo Giovannoni, Roberto Sommavilla, Manuela Kaspar, Eveline Trachsel, Dario Neri.   

Abstract

The isolation of mammalian cell lines capable of high-yield expression of recombinant antibodies is typically performed by screening multiple individual clones by limiting dilution techniques. A number of experimental strategies have recently been devised to identify high-expressing clones, but protocols are often difficult to implement, time consuming, costly and limited in terms of number of clones which can be screened. In this article, we describe new vectors for the expression of recombinant antibodies in IgG format and in other formats, based on the single-chain Fv module, as well as a high-throughput screening procedure, based on the direct staining of antibodies transiting the membrane of a stably transfected cell, followed by preparative sorting using a high-speed cell sorter. This procedure allows, in one step, to deposit single cells into individual wells of a 96-well microtiter plate (thus facilitating cloning) and to preferentially recover those rare cell populations which express dramatically higher levels of recombinant antibody. Using cell cultures followed by affinity purification techniques, we could confirm that the new vectors and the new screening procedure reliably yield high-expression clones and homogenous protein preparations. We expect that these techniques should find broad applicability for both academic and industrial antibody engineering research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022802     DOI: 10.1093/protein/gzn068

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  13 in total

1.  Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.

Authors:  Roberta Bianchi; Eliane Fischer; Don Yuen; Ellen Ernst; Alexandra M Ochsenbein; Lu Chen; Vivianne I Otto; Michael Detmar
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

2.  High yield of human monoclonal antibody produced by stably transfected Drosophila schneider 2 cells in perfusion culture using wave bioreactor.

Authors:  Lulan Wang; Hongxing Hu; Jianjun Yang; Feng Wang; Christian Kaisermayer; Paul Zhou
Journal:  Mol Biotechnol       Date:  2012-10       Impact factor: 2.695

3.  Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3.

Authors:  Stefanie Pfaffen; Katharina Frey; Irène Stutz; Christoph Roesli; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-20       Impact factor: 9.236

4.  Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.

Authors:  Emil Bujak; Francesca Pretto; Dario Neri
Journal:  Invest New Drugs       Date:  2015-05-19       Impact factor: 3.850

5.  Production of anti TNF-α antibodies in eukaryotic cells using different combinations of vectors carrying heavy and light chains.

Authors:  Dmitriy Balabashin; Elena Kovalenko; Viktoria Toporova; Teimur Aliev; Anna Panina; Elena Svirshchevskaya; Dmitry Dolgikh; Mikhail Kirpichnikov
Journal:  Cytotechnology       Date:  2014-06-18       Impact factor: 2.058

6.  Ubiquitin Phosphorylation at Thr12 Modulates the DNA Damage Response.

Authors:  Franziska Walser; Monique P C Mulder; Benoît Bragantini; Sibylle Burger; Tatiana Gubser; Marco Gatti; Maria Victoria Botuyan; Alessandra Villa; Matthias Altmeyer; Dario Neri; Huib Ovaa; Georges Mer; Lorenza Penengo
Journal:  Mol Cell       Date:  2020-10-05       Impact factor: 17.970

7.  A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.

Authors:  A Palumbo; F Hauler; P Dziunycz; K Schwager; A Soltermann; F Pretto; C Alonso; G F Hofbauer; R W Boyle; D Neri
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

8.  Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.

Authors:  J K J Ahlskog; C Schliemann; J Mårlind; U Qureshi; A Ammar; R B Pedley; D Neri
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

9.  Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.

Authors:  Rémy Gébleux; Marco Stringhini; Ruben Casanova; Alex Soltermann; Dario Neri
Journal:  Int J Cancer       Date:  2016-12-30       Impact factor: 7.396

10.  Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Rémy Gébleux; Sarah Wulhfard; Giulio Casi; Dario Neri
Journal:  Mol Cancer Ther       Date:  2015-08-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.